Solely dedicated to discovery & development of novel therapeutics

LegoChem Biosciences is a unique company founded by people with
expertise & enthusiasm for developing novel therapeutics.
Since our foundation in 2006 we have focused on the research and
development of ADC (Antibody-Drug Conjugate), Anti-biotics,
Anti-coagulants & Anti-cancer therapeutics based on our
proprietary platform technology LegoChemistry™.

[Media Releases] LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program   DAEJEON, South Korea--LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today a worldwide license agreement with Iksuda Therapeutics (“Iksuda”) for the development and commercialization of LCB73, a CD19-targeted ADC candidate for hematological tumors.   Under the terms of the agreement, Iksuda will make an upfront payment of USD 5 million and LCB is eligible to receive development, regulatory and commercial milestone payments of up to USD 222 million as well as royalties on commercial sales. LCB is also entitled to receive a prearranged percentage of sublicense revenue if Iksuda enters into license agreement with third party companies. All payments will be shared with LCB’s partner Light Chain Bioscience (Novimmune SA).   LCB73 has been generated in a partnership between LCB and Swiss-based Light Chain Bioscience’s (Novimmune SA) by combining LCB’s cancer-selectively activated next-generation linker and toxin platform with Light Chain Bioscience’s proprietary antibody targeting CD19. Preclinical data of LCB73 along with the clinical outcome of other CD19-targeted therapies suggest that the ADC may be an effective treatment option for various B-cell hematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.   “We are very pleased to expand our partnership with Iksuda to advance the development of LCB73, in addition to the recent license agreement which enables the application of our ADC platform to Iksuda’s pipeline of Next Generation ADCs,” said Dr. Yong-Zu Kim, CEO & President of LCB. “This particular ADC program will set a significant milestone as it is our first lead ADC candidate utilizing our next-generation prodrug payload, whose commercial and clinical potential will be explored through this collaboration.”   “We have been very impressed with preclinical data using LCB73 which have demonstrated significant single-agent anti-cancer activity in B cell malignancies and a competitive toxicity profile,” said Dr. David Simpson, CEO of Iksuda. “We look forward to advancing this candidate into the clinic in the most efficient manner, utilizing our extensive UK and US based ADC expertise to drive preclinical and clinical development activities.”
2020.05.15
[Press Release] LegoChem Biosciences and Iksuda Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
LegoChem Biosciences and Iksuda Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates   - Agreement grants Iksuda an access to Legochem Biosciences’ next generation payload and proprietary linker to discover and advance lead ADC for difficult-to-treat tumours   - DAEJEON, Apr 14, 2020 -   LegoChem Biosciences, Inc. (“LCB”), based in DaeJeon South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology. Iksuda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology, ConjuALL, including LCB’s cancer-selectively activated payloads as well as its proprietary linker and conjugation platform, to research, develop and commercialize targeted anti-cancer therapeutics. Under the terms of the agreement, Iksuda has rights to use the LCB technology to develop therapeutics directed to up to three undisclosed targets.     LCB will receive development, regulatory and commercial milestone payments of up to $407.25 million as well as royalties on the sales of any resulting ADC products. In addition, LCB is eligible to receive a prearranged percentage of sublicense revenue if Iksuda enters into License agreement with third party companies.   Iksuda, a UK-based biotech company established in 2012, is focusing on the development of novel ADC therapeutics. Iksuda has built up world-class R&D team including Dr. Robert Lutz, CSO of Iksuda, who is a global ADC expert and has significantly contributed to the successful development and commercialization of a blockbuster drug, Kadcyla as well as several other ADC therapeutics when he was at Immunogen.   “We plan to advance ADC products from this partnership to clinical stage as quickly as possible” said Dr. David Simpson, the CEO of Iksuda. “This collaboration will allow us to leverage LCB's next-generation linker and payload platform and combining it with our expertise and capabilities in ADC development will enable success.”   “We are pleased to collaborate with Iksuda given its experience and expertise in ADC research and development. This agreement highlights that not only is LCB delivering unique, differentiated linker technology, but great potential and wide applicability of our proprietary payload, is also now endorsed by global experts from Iksuda,” said Dr. Yong-Zu Kim, the CEO & President of LCB. “Our goal is to demonstrate the competitiveness of LegoChem Bio in human trials in a most efficient way by applying our ADC platform to Iksuda’s pipelines.”
2020.04.14
[Press Release] LegoChem Biosciences and Takeda Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
LegoChem Biosciences and Takeda Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology   – Takeda obtains rights to LCB’s ADC platform for multiple targets –   - DAEJEON, March 22, 2019 - LegoChem Biosciences, Inc. (“LCB”) announced today that it has entered a research collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the development of antibody-drug conjugates in immuno-oncology.   Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology, ConjuALL, including LCB’s proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics. Under the terms of the agreement, Takeda has rights to use the LCB technology to develop therapeutics directed to up to three undisclosed targets.   LCB will receive $7.25 million in upfront and near-term milestone payments.  In addition, LCB is eligible to receive development, regulatory and commercial milestone payments of up to $404 million as well as royalties on the sales of any resulting ADC products.   "We are delighted to collaborate with Takeda given its experience and expertise in oncology research and development. We believe this partnership provides further validation of our proprietary ADC platform technology that can be used for different oncology applications including immuno-oncology therapeutics," said Yong-Zu Kim, CEO of LCB. "Our goal is to demonstrate the competitiveness of LCB in the global ADC market by applying our linker and payload platform technologies to our own and our collaborators’ pipelines."     About LegoChem Biosciences LegoChem Biosciences(Kosdaq: 141080) is a biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry™ & ADC platform technology ConjuAll™.  Since its foundation in 2006, LCB has focused on the research and development of ADC (Antibody-Drug-Conjugates), antibiotics, anticoagulants and anticancer therapeutics based on proprietary platform technologies. About ConjuAllTM ConjuAllTM is a next-generation ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. Our platform provides solutions for site-specific conjugation, linker stability and efficient payload release which are three major unmet needs in ADC development.   MedCI LLC and Foley Hoag LLC, represented LCB in the transaction.
2019.03.22